Compare Charles River Laboratories Intl. Inc (CRL) vs Nebius Group NV (NBIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Nebius Group NV — how do they compare? Charles River Laboratories Intl. Inc trades at $228.98 (market cap $11.14B), while Nebius Group NV trades at $198.54 (market cap $49.28B). The key difference: Nebius Group NV is far larger — about 4.4× Charles River Laboratories Intl. Inc's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Nebius Group NV nearer its low. Which is the better fit depends on your goals.
| CRL | NBIS | |
|---|---|---|
Market Cap | $11.14B | $49.28B |
Sector | Health | Technology |
52-Week High | $233.60 | $286.69 |
52-Week Low | $145.57 | $50.40 |
Enterprise Value | $14.00B | $49.48B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
NBIS trades at $210.51, down 4.16% today amid bearish technical signals, though it maintains strong analyst support with 87.5% buy ratings and a $248 consensus price target. The company shows impressive revenue growth projections from $530M in 2025 to $878M in 2026, with net income margin expanding to 93.09%. Recent positive developments include a $1 billion compute deal with Reflection AI and strategic infrastructure expansion, though valuation ratios remain elevated with P/E at 74.94.
The outlook remains constructive given robust AI infrastructure demand and significant contract wins, but investors face risks from Meta's potential cloud competition and high valuations. Near-term price action suggests consolidation near support at $204, with upside potential to resistance at $218 if earnings momentum continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Nebius Group NV
Nebius Group N.V. is a technology company specializing in AI, machine learning, and cloud computing solutions. The company provides a range of enterprise-level cloud services, including large-scale data processing, advanced analytics, and AI model development and deployment. Nebius Group focuses on serving businesses that require high-performance, scalable, and secure infrastructure to handle complex computational tasks and accelerate their digital transformation.
Read more on NBIS →
